NovoCure (NVCR) Competitors $30.80 +0.40 (+1.32%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NVCR vs. SOLV, SNN, PEN, GKOS, BLCO, INSP, PRCT, AXNX, NVST, and NARIShould you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Axonics (AXNX), Envista (NVST), and Inari Medical (NARI). These companies are all part of the "medical equipment" industry. NovoCure vs. Solventum Smith & Nephew Penumbra Glaukos Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics Axonics Envista Inari Medical NovoCure (NASDAQ:NVCR) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings. Which has preferable valuation and earnings, NVCR or SOLV? Solventum has higher revenue and earnings than NovoCure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovoCure$577.74M5.77-$207.04M-$1.40-22.00Solventum$8.26B1.40N/AN/AN/A Does the MarketBeat Community favor NVCR or SOLV? NovoCure received 475 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 63.72% of users gave NovoCure an outperform vote while only 5.56% of users gave Solventum an outperform vote. CompanyUnderperformOutperformNovoCureOutperform Votes47663.72% Underperform Votes27136.28% SolventumOutperform Votes15.56%Underperform Votes1794.44% Do insiders and institutionals hold more shares of NVCR or SOLV? 84.6% of NovoCure shares are held by institutional investors. 6.3% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is NVCR or SOLV more profitable? Solventum has a net margin of 0.00% compared to NovoCure's net margin of -25.93%. Solventum's return on equity of 0.00% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets NovoCure-25.93% -41.48% -12.74% Solventum N/A N/A N/A Do analysts recommend NVCR or SOLV? NovoCure currently has a consensus price target of $32.67, indicating a potential upside of 6.06%. Solventum has a consensus price target of $68.29, indicating a potential upside of 2.18%. Given NovoCure's stronger consensus rating and higher possible upside, analysts plainly believe NovoCure is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Solventum 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer NVCR or SOLV? In the previous week, Solventum had 11 more articles in the media than NovoCure. MarketBeat recorded 14 mentions for Solventum and 3 mentions for NovoCure. Solventum's average media sentiment score of 1.23 beat NovoCure's score of 0.73 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNovoCure beats Solventum on 8 of the 14 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCR vs. The Competition Export to ExcelMetricNovoCureSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.29B$4.36B$5.01B$9.08BDividend YieldN/A41.46%4.87%4.21%P/E Ratio-22.0025.01135.0717.15Price / Sales5.7745.671,120.63116.80Price / CashN/A43.4640.5837.88Price / Book9.097.364.754.78Net Income-$207.04M$13.64M$118.50M$225.60M7 Day Performance-7.81%-2.82%-1.85%-1.21%1 Month Performance80.22%0.54%11.28%3.09%1 Year Performance130.71%41.80%29.92%16.48% NovoCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCRNovoCure2.7417 of 5 stars$30.80+1.3%$32.67+6.1%+138.4%$3.29B$577.74M-22.001,453SOLVSolventum1.3032 of 5 stars$69.65+0.1%$68.29-2.0%N/A$12.03BN/A0.0022,000Positive NewsSNNSmith & Nephew3.7078 of 5 stars$25.66+0.5%N/A-7.3%$11.22B$5.55B13.0318,452News CoveragePENPenumbra4.2288 of 5 stars$248.26+1.1%$252.42+1.7%-1.8%$9.53B$1.16B285.524,200Analyst ForecastGKOSGlaukos4.115 of 5 stars$143.55+3.3%$143.17-0.3%+89.5%$7.91B$360.35M-46.00780Analyst ForecastShort Interest ↓BLCOBausch + Lomb3.0993 of 5 stars$18.60flat$20.58+10.7%+16.9%$6.55B$4.68B-17.7113,300INSPInspire Medical Systems4.6549 of 5 stars$189.70+1.0%$233.58+23.1%+1.7%$5.68B$755.59M175.541,011Positive NewsPRCTPROCEPT BioRobotics2.7844 of 5 stars$90.97+1.9%$97.86+7.6%+102.9%$4.75B$136.19M0.00626Positive NewsAXNXAxonics1.4327 of 5 stars$70.98+0.8%$71.00+0.0%+20.9%$3.63B$366.38M-591.45610High Trading VolumeNVSTEnvista3.9012 of 5 stars$19.72+1.3%$20.65+4.7%-21.1%$3.39B$2.50B-2.5112,800NARIInari Medical3.3152 of 5 stars$55.45-0.3%$58.89+6.2%-11.9%$3.25B$574.50M-41.181,300Analyst ForecastInsider Trade Related Companies and Tools Related Companies Solventum Alternatives Smith & Nephew Alternatives Penumbra Alternatives Glaukos Alternatives Bausch + Lomb Alternatives Inspire Medical Systems Alternatives PROCEPT BioRobotics Alternatives Axonics Alternatives Envista Alternatives Inari Medical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NVCR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVCR Stock Alerts